Cynthia Comella1, Joaquim J Ferreira2,3, Emilie Pain4, Marion Azoulai4, Savary Om5. 1. Department of Neurology, Rush University Medical Center, 1725 West Harrison St. Suite 755, Chicago, IL, 60612, USA. Cynthia_Comella@rush.edu. 2. Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. 3. CNS, Campus Neurológico Sénior, Torres Vedras, Portugal. 4. Carenity, Paris, France. 5. Global Medical Affairs, Ipsen Pharma, Boulogne-Billancourt, France.
Abstract
BACKGROUND: Botulinum neurotoxin type A (BoNT-A) is an effective pharmacological treatment for the management of cervical dystonia (CD) that requires repeated administration at variable intervals. We explored patient perceptions of the impact of CD and the waning of BoNT-A therapeutic effects. METHODS: An internet-based survey was conducted through Carenity, a global online patient community, from May to September 2019. Eligible respondents were adults with CD who had ≥ 2 previous BoNT-A injections. RESULTS: 209 respondents (81% females; mean age of 49.7 years) met the screening criteria. The mean BoNT-A injection frequency was 3.9 injections/year. The mean reported onset of BoNT-A therapeutic effect was 11.7 days and the time to peak effect was 4.5 weeks. Symptom re-emergence between injections was common (88%); the time from injection to symptom re-emergence was 73.6 days (~ 10.5 weeks). Treatment was not reported to completely abolish symptoms, even at peak effect. However, symptom severity was rated (0 = no symptoms; 10 = very strong symptoms) as lowest at the peak of treatment effects (mean scores ~ 3/10), increasing as the effects of treatment start waning (~ 5.5/10) and was strongest one day before the next session (~ 7-8/10). The impact of CD on quality of life followed the same 'rollercoaster' pattern. CONCLUSIONS: This survey highlights the burden of CD symptoms, even in patients undergoing regular treatment. Symptom re-emergence is common and has significant impact on daily activities and quality of life. Greater awareness of the therapeutic profile of BoNT-A treatment should lead to better informed therapeutic discussions and planning.
BACKGROUND: Botulinum neurotoxin type A (BoNT-A) is an effective pharmacological treatment for the management of cervical dystonia (CD) that requires repeated administration at variable intervals. We explored patient perceptions of the impact of CD and the waning of BoNT-A therapeutic effects. METHODS: An internet-based survey was conducted through Carenity, a global online patient community, from May to September 2019. Eligible respondents were adults with CD who had ≥ 2 previous BoNT-A injections. RESULTS: 209 respondents (81% females; mean age of 49.7 years) met the screening criteria. The mean BoNT-A injection frequency was 3.9 injections/year. The mean reported onset of BoNT-A therapeutic effect was 11.7 days and the time to peak effect was 4.5 weeks. Symptom re-emergence between injections was common (88%); the time from injection to symptom re-emergence was 73.6 days (~ 10.5 weeks). Treatment was not reported to completely abolish symptoms, even at peak effect. However, symptom severity was rated (0 = no symptoms; 10 = very strong symptoms) as lowest at the peak of treatment effects (mean scores ~ 3/10), increasing as the effects of treatment start waning (~ 5.5/10) and was strongest one day before the next session (~ 7-8/10). The impact of CD on quality of life followed the same 'rollercoaster' pattern. CONCLUSIONS: This survey highlights the burden of CD symptoms, even in patients undergoing regular treatment. Symptom re-emergence is common and has significant impact on daily activities and quality of life. Greater awareness of the therapeutic profile of BoNT-A treatment should lead to better informed therapeutic discussions and planning.
Authors: David M Simpson; Mark Hallett; Eric J Ashman; Cynthia L Comella; Mark W Green; Gary S Gronseth; Melissa J Armstrong; David Gloss; Sonja Potrebic; Joseph Jankovic; Barbara P Karp; Markus Naumann; Yuen T So; Stuart A Yablon Journal: Neurology Date: 2016-04-18 Impact factor: 9.910
Authors: A Albanese; F Asmus; K P Bhatia; A E Elia; B Elibol; G Filippini; T Gasser; J K Krauss; N Nardocci; A Newton; J Valls-Solé Journal: Eur J Neurol Date: 2011-01 Impact factor: 6.089
Authors: Werner Poewe; Pierre Burbaud; Giovanni Castelnovo; Wolfgang H Jost; Andres O Ceballos-Baumann; Marta Banach; Anna Potulska-Chromik; Joaquim J Ferreira; Katalin Bihari; Edvard Ehler; Martin Bares; Lyudmyla A Dzyak; Anna N Belova; Emmanuel Pham; Wenzhong Jerry Liu; Philippe Picaut Journal: Mov Disord Date: 2016-09-21 Impact factor: 10.338
Authors: Lisa Klingelhoefer; Kallol R Chaudhuri; Christoph Kamm; Pablo Martinez-Martin; Kailash Bhatia; Anna Sauerbier; Maximilian Kaiser; Carmen Rodriguez-Blazquez; Bettina Balint; Robert Untucht; Lynsey J Hall; Lauritz Mildenstein; Miriam Wienecke; Davide Martino; Olaf Gregor; Alexander Storch; Heinz Reichmann Journal: Ann Clin Transl Neurol Date: 2019-09-27 Impact factor: 4.511